Nuvalent (NUVL) Stock Forecast & Price Target

$102.30

+3.20 (+3.23%)

(As of 09/30/2024 ET)

Nuvalent - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
1

Hold
0

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Nuvalent in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 10 have given a buy rating, and 1 has given a strong buy rating for NUVL.

Consensus Price Target

$111.00
8.50% Upside

According to the 12 analysts' twelve-month price targets for Nuvalent, the average price target is $111.00. The highest price target for NUVL is $135.00, while the lowest price target for NUVL is $97.00. The average price target represents a forecasted upside of 8.50% from the current price of $102.30.

Get the Latest News and Ratings for NUVL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Nuvalent and its competitors.

NUVL Analyst Ratings Over Time

Type	Current Forecast 10/2/23 to 10/1/24	1 Month Ago 9/2/23 to 9/1/24	3 Months Ago 7/4/23 to 7/3/24	1 Year Ago 10/2/22 to 10/2/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	9 Buy rating(s)	4 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$111.00	$92.78	$90.78	$51.33
Forecasted Upside	8.50% Upside	8.98% Upside	25.99% Upside	12.06% Upside
Consensus Rating	Moderate Buy	Buy	Moderate Buy	Moderate Buy

Does Elon Musk control the U.S. gov’t? (Ad)

Elon has been advising the government to reopen America’s nuclear facilities for years, and now, with the help of Biden’s ADVANCE act, these facilities are once again going back online just as he requested. One company is poised to benefit from America’s nuclear revival like no other. Elon Musk is one of the few people who knows this.

Watch this new documentary and you’ll discover what Elon knows,

NUVL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NUVL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Nuvalent Stock vs. The Competition

Type	Nuvalent	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	8.50% Upside	823.01% Upside	6.15% Upside
News Sentiment Rating	Positive News See Recent NUVL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/16/2024	The Goldman Sachs Group 2 of 5 stars	R. Law Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
9/16/2024	Wedbush 3 of 5 stars		Boost Target	Outperform ➝ Outperform	$99.00 ➝ $115.00	+7.26%
9/16/2024	Guggenheim 3 of 5 stars		Boost Target	Buy ➝ Buy	$99.00 ➝ $105.00	-2.07%
9/16/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$102.00 ➝ $132.00	+24.53%
9/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$115.00 ➝ $135.00	+54.37%
9/4/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$90.00 ➝ $100.00	+18.23%
Get the Latest News and Ratings for NUVL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter.
8/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Lawson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$100.00	+18.11%
7/29/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Zhu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/17/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$97.00	+50.48%
4/1/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Berens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
4/1/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$69.00 ➝ $110.00	+46.49%
2/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$105.00	+26.16%
8/8/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$42.00	-5.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:25 AM ET.

NUVL Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Nuvalent is $111.00, with a high forecast of $135.00 and a low forecast of $97.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There is currently 1 sell rating, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares.
: According to analysts, Nuvalent's stock has a predicted upside of 8.50% based on their 12-month stock forecasts.
: Over the previous 90 days, Nuvalent's stock had 2 upgrades by analysts.
: Nuvalent has been rated by research analysts at Barclays, BMO Capital Markets, Guggenheim, JPMorgan Chase & Co., Lifesci Capital, Stifel Nicolaus, The Goldman Sachs Group, and Wedbush in the past 90 days.
: Analysts like Nuvalent more than other "medical" companies. The consensus rating score for Nuvalent is 2.92 while the average consensus rating score for "medical" companies is 2.78. Learn more on how NUVL compares to other companies.